Blog

July 28, 2026

By: List Labs

Bacterially Derived Therapeutic Proteins: Why Early Process Strategy Matters By Kent Davis, and John Neville, PhD List Labs July 2026 Bacterial expression systems remain one of the most important platforms for producing therapeutic proteins, bacterial-derived proteins, toxins, toxoids, enzymes, vaccine components, and other biologically active molecules. Their speed, scalability, well-understood genetics, and long history of [...]

June 22, 2026

By: List Labs

C. difficile Toxin A and Toxin B: Roles in CDI Research, Diagnostics, Vaccines, and Therapeutics By Stacy Burns-Guydish, PhD, and John Neville, PhD List Labs Clostridioides difficile infection is primarily driven by toxin-mediated damage caused by toxin A and toxin B, also known as TcdA and TcdB. These toxins are central to CDI pathogenesis and [...]

September 19, 2022

By: List Labs

List Labs is an experienced contract development and manufacturing organization (CDMO) harnessing bacteria’s potential for a healthier world. We offer a refreshingly flexible approach to clients seeking a CDMO for Live Biotherapeutic Products (LBP) derived from beneficial bacteria. Partner with List Labs as your CDMO and experience our uniquely collaborative and transparent culture. Why Choose […]